Q&A: Symbiosis: US FDA boost at Scottish aseptic viral vector plant

Colin MacKay, CEO of Symbiosis Pharmaceutical Services, recently took part in a Q&A interview with BioProcess Insider, discussing US Food and Drug Administration (FDA) approval and what it means for Symbiosis in terms of meeting industry demands now and post-Brexit.The article provides insight into the significance of US FDA accreditation, the Innovate UK grant and the challenges Brexit poses for Symbiosis and… Read More

Symbiosis secures FDA viral vector process approval

Stirling, UK – SYMBIOSIS Pharmaceutical Services, a fast-growing specialist sterile manufacturing CDMO, has reported FDA approval for its viral vector manufacturing fill/finish process at its biologics manufacturing facility located in Scotland, UK.Symbiosis recently hosted a successful inspection by the United States Government Food and Drug Administration (FDA) for the aseptic manufacture of viral vector products for commercial supply into the U.S market… Read More

Cobra Biologics and Symbiosis awarded £1.9m ($2.5m USD) Innovate UK Grant

Keele and Stirling, UK, 1 February 2018: Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in sterile Fill Finish, today announced that they have been awarded a 16-month collaborative grant of £1.9m from Innovate UK.The grant will position the partner companies as globally recognised… Read More

Cover story: Scottish Specialty CMO Thrives as ‘One-Stop-Shop’ Becomes the Trend

We were recently invited to feature in Pharmaceutical Processing’s Apri/May edition with a cover story on how Symbiosis Pharmaceutical Services has thrived as a small-scale, niche sterile manufacturer depsite the ‘one-stop-shop’ model becoming the trend.Throughout the article, Colin Mackay outlines how our facility in Stirling, Scotland has addressed specific gaps in the sterile drug product manufacturing marketplace. He also addresses not only our… Read More

Roundtable: Aseptic Manufacturing Trends

CEO of Symbiosis Pharmaceutical Services, Colin Mackay, was recently invited to participate in a roundtable discussion on aseptic manufacturing trends for Contract Pharma along with leaders from Recipharm and ChargePoint Technology.The resulting article explores key trends and challenges when it comes to aseptic manufacturing.In the article, Colin explains: “The development of robust single-use manufacturing technology has been a step-change in the sector, enabling more efficient… Read More

Scottish CMO opens US office

Symbiosis Pharmaceutical Services is set to open an office in North America in response to continued demand from US-based biotechnology companies for its vial-filling expertise.The sterile filling specialist will open a commercial site in Cambridge, Boston, MA, to support its clients on both the East and West Coast, as well as giving the contract manufacturing organisation (CMO) a base for reaching new customers… Read More

Q&A: Parenteral Outsourcing Trends

Our own Colin MacKay, CEO of Symbiosis Pharmaceutical Services, was recently invited to participate in a roundtable discussion assessing the trends driving parenteral manufacturing for an article for Contract Pharma.The resulting article explores the trends that are fuelling the demand for parenteral manufacturing, the changing structure of the CMO industry and the impact on biotech and small pharma companies needing to outsource… Read More

Q&A: Biotech growth driving ‘surge in demand’

Here at Symbiosis Pharmaceutical Services we’re preparing for increasing growth in the outsourcing sector following an investment at our sterile filling facility and the appointment of Dr. Tom Scullion, US Business Development Manager.Having joined the team to support increased demand for our sterile filling services from biotechs, Tom was recently invited to talk about his role here at Symbiosis and his insight into where… Read More

Get In Touch.


By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.